Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UNI836
- Development stage
- Unknown
- Lead developer
- UNION therapeutics
- Modality
- Small Molecules
01
Overview
UNI836 is a clinical-stage drug candidate being developed by UNION therapeutics, specifically designated for a veterinary program. Currently in Phase 2 development, the asset is part of UNION's strategy to repurpose and optimize well-characterized small molecules for new therapeutic applications. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed in company pipeline documentation, UNION therapeutics generally focuses on addressing unmet needs in infectious and inflammatory diseases through medicinal chemistry optimization of established compounds. UNI836 represents the company's expansion of its core therapeutic expertise into the animal health sector.
Beyond the preview
Go deeper on UNI836.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UNI836.